The information in these press releases is accurate only as of the date of the particular press release. Theravance does not update press releases once they have been made public. Press releases may contain forward-looking statements and future events or actual results could differ materially from those projected in the forward-looking statements.
 |
Theravance to Present at Investor Conferences in June 2013
May 23, 2013
|
13.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/23/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the following investor conferences in June 2013:
Jefferies 2013 Global Healthcare Conference
Grand Hyatt, New York City, NY
...
|
|
Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement
May 13, 2013
|
166.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA and DUBLIN, IRELAND -- (Marketwired) -- 05/13/13 --
Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN) today announced that they have entered into a royalty participation agreement wherein Elan will purchase a participation interest in potential future royalty payments related to four respiratory progr...
|
|
BREO(TM) ELLIPTA(TM) Gains US Approval for the Treatment of COPD
May 10, 2013
|
159.4 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/10/13 --
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with...
|
|
Theravance Reports First Quarter 2013 Financial Results
Apr 25, 2013
|
82.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 --
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended March 31, 2013. Revenue for the first quarter of 2013 was $1.3 million. Net loss for the first quarter of 2013 was $37.4 million or $0.39 per share. Cash and cash equivalents, short-t...
|
|
Theravance Announces Plan to Separate Late-Stage Partnered Respiratory Assets From Biopharmaceutical Operations
Apr 25, 2013
|
19.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 --
Theravance, Inc. (NASDAQ: THRX)
Intention to create two independent publicly traded companies with differing business objectives and opportunities
One company will continue to manage the late-stage partnered respiratory assets and associate...
|
|
Theravance to Present at Investor Conferences in May 2013
Apr 23, 2013
|
13.3 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/23/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that Theravance management is scheduled to present at the following investor conferences in May 2013:
12th Annual Needham Healthcare Conference
Westin Grand Central Hotel, New York City, NY
Wednesday, May 1, 2...
|
|
GSK and Theravance Announce Regulatory Submission for ANORO™ ELLIPTA™ (UMEC/VI) in Japan
Apr 22, 2013
|
14.7 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 22, 2013) - GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chroni...
|
|
Theravance to Webcast 2013 Annual Meeting of Stockholders on April 24, 2013
Apr 18, 2013
|
10.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/18/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that it will webcast its 2013 Annual Meeting of Stockholders at 1:00 p.m. Pacific Daylight Time on Wednesday, April 24, 2013.
An accompanying listen-only conference call will be held at 4:00 p.m. Eastern Daylight Time. To participa...
|
|
FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD
Apr 17, 2013
|
18.6 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/17/13 --
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted that the efficacy and safety data provide substantial evidence to support approval of ...
|
|
Trading in Theravance Common Stock Halted
Apr 17, 2013
|
10.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/17/13 --
Theravance, Inc. (NASDAQ: THRX) today announced that NASDAQ halted trading of Theravance common stock this morning, April 17, 2013. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to discuss the new drug application (NDA) 204275, fo...
|
|
Theravance to Report First Quarter 2013 Financial Results on April 25, 2013
Apr 11, 2013
|
10.5 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/11/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended March 31, 2013 after market close on Thursday, April 25, 2013.
An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live...
|
|
Clinigen and Theravance Announce Exclusive Commercialization Agreement in the EU for VIBATIV(R) (telavancin)
Mar 11, 2013
|
21.5 KB |
|
| |
BURTON-ON-TRENT, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/11/13 --
Clinigen Group plc (LSE: CLIN) (AIM: CLIN) and Theravance, Inc. (NASDAQ: THRX) today announced that they have entered into an exclusive commercialization agreement in the European Union (EU) and certain other countries located in Europe for VIBATIV® ...
|
|
Theravance to Present at Investor Conferences in March 2013
Feb 21, 2013
|
13.0 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/21/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the following investor conferences in March 2013:
Cowen and Company
The Boston Marriott Copley Place, Boston, ...
|
|
GSK and Theravance Announce FDA Acceptance of New Drug Application (NDA) Submission in the US for ANORO ELLIPTA(TM) for COPD
Feb 19, 2013
|
16.1 KB |
|
| |
LONDON and SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/19/13 --
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the New Drug Application (NDA) for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI, for patients with chronic obstructive pulmonary disease (COPD), has been accepted by ...
|
|
Theravance to Present at the 2013 Citi Global Healthcare Conference
Feb 13, 2013
|
12.8 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/13/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the 2013 Citi Global Healthcare Conference on Wednesday, February 27, 2013, at 3:00 p.m. EST. The conference will be held from February 25-27, 2013 at the...
|
|
Theravance Reports Fourth Quarter and Full Year 2012 Financial Results
Feb 12, 2013
|
77.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/12/13 --
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the fourth quarter and full year ended December 31, 2012. Revenue for the full year was $135.8 million. Net loss for the fourth quarter and full year of 2012 was $31.3 million and $18.5 million, respect...
|
|
Theravance to Present at the Leerink Swann Global Healthcare Conference 2013
Jan 31, 2013
|
12.8 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/31/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that that Michael W. Aguiar, Theravance's Senior Vice President and Chief Financial Officer, is scheduled to present at the Leerink Swann Healthcare Conference 2013 on Thursday, February 14, 2013, at 8:30 a.m. EST. The conference will be held ...
|
|
Theravance to Report Fourth Quarter and Full Year 2012 Financial Results on February 12, 2013
Jan 29, 2013
|
10.4 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/29/13 --
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2012 after market close on Tuesday, February 12, 2013.
An accompanying conference call will be held at 5:00 p.m. Eastern Standard Tim...
|
|
Theravance Announces Closing of Public Offering of $287.5 Million of Convertible Subordinated Notes
Jan 24, 2013
|
11.7 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/24/13 -- Theravance, Inc. (NASDAQ: THRX) (the "Company"), a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies, announced that it closed the sale of its previously announced underwritten public offering of $287...
|
|
Theravance Announces Exercise by Underwriters of Option to Purchase Additional $37.5 Million Convertible Subordinated Notes
Jan 22, 2013
|
11.6 KB |
|
| |
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/22/13 -Theravance, Inc. (NASDAQ: THRX) (the "Company"), a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies, announced that the underwriters of its 2.125% convertible subordinated notes due 2023 (t...
|
|
|
